Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1,2-dimethylhydrazine is an organic compound belonging to the class of alkylhydrazines, specifically a hydrazine derivative with the formula C2H8N2. It is a colorless, highly toxic, volatile liquid with an ammonia-like odor, notable for being a **potent DNA-methylating agent and carcinogen**. It has no commercial value but is extensively used in laboratory research, particularly to induce colon tumors in experimental animals for cancer research. Mechanistically, its carcinogenic effect is due to the formation of DNA adducts by methylation, leading to mutations and tumorigenesis, especially in the colon[3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1,2-dimethylhydrazine.